Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000902664-25-003881·Design Therapeutics, Inc.
Schedule 13G ownership disclosure
Design Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 25056L103
Event date: 2025-08-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Point72 Asset Management, L.P.
Shares: 2,942,719.00 · Class: 5.2%
- Point72 Capital Advisors, Inc.
Shares: 2,942,719.00 · Class: 5.2%
- Steven A. Cohen
Shares: 2,942,719.00 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-003881
- Form type
- SCHEDULE 13G
- Filer
- Design Therapeutics, Inc.
- CIK
- CIK 1807120
- Filed
- Aug 28, 2025
- Reporting period
- Aug 27, 2025
- Description
- Schedule 13G beneficial ownership